An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy.

Trial Profile

An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms MARC-2
  • Most Recent Events

    • 24 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 12 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 08 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top